In a market where long‑term equity returns still outpace most other asset classes, investors are being urged to stay the course and consider companies that combine steady cash flow with reliable dividend growth. The latest analysis points to three U.S. health‑care giants whose dividend yields range from roughly 2.4% to 6.2% and whose business fundamentals suggest continued payout capacity.
Pfizer (PFE) offers a forward dividend yield of about 6.2%, the highest among the three. While the drugmaker’s recent earnings have been muted and its COVID‑19 vaccine revenue has receded, the company is banking on a diversified pipeline that includes the cancer drug Padcev, the RSV vaccine Abrysvo and an investigational long‑acting weight‑loss therapy (PF‑3944). Analysts note that despite near‑term revenue pressure and upcoming patent expirations, Pfizer’s commitment to raising its dividend each quarter signals confidence in medium‑term cash generation.
Abbott Laboratories (ABT) posted a 4.8% year‑over‑year rise in second‑quarter comparable sales to $12.6 billion, driven primarily by its medical‑device segment. The firm’s dividend yield stands at 2.43%, and it has increased payouts for more than five decades, earning it “Dividend King” status. Abbott’s recent $21 billion acquisition of Exact Sciences is expected to broaden its reach into cancer diagnostics, while its MitraClip device and FreeStyle Libre glucose monitors continue to capture market share.
Medtronic (MDT) recorded a 13.7% year‑over‑year increase in first‑quarter fiscal 2027 revenue to $9.8 billion, with cardiac‑ablation solutions posting an 88% surge. The company’s dividend yield is 3.07% and it is on the cusp of joining the Dividend Kings after 49 consecutive payout hikes. Medtronic is also advancing its Hugo robotic‑assisted surgery system, which is gaining traction in urology and may expand into gynecology and general surgery. A planned spin‑off of its diabetes‑care unit is expected to sharpen the firm’s focus on higher‑margin hospital‑based devices.
For income‑oriented investors, the trio offers a blend of high yields and growth catalysts. Pfizer’s elevated yield comes with higher risk tied to patent cliffs, whereas Abbott’s steadier payout is underpinned by diversified device sales and strategic acquisitions. Medtronic’s moderate yield is supported by robust sales momentum and upcoming product rollouts. Together, they illustrate how dividend‑paying health‑care stocks can provide both cash flow and exposure to emerging therapeutic trends.